A study on insulin and its analogues for control of abnormal glycosylated haemoglobin in controlled or near-controlled type II diabetes mellitus patients on oral hypoglycaemic agents

Journal, Indian Academy of Clinical Medicine

Volumn 15, Issue 2, 2014, Pages 106-110

  Talib, S H ^a   Gulve, Vijaykumar ^a   Tapadia, Ashish ^a   Inamdar, Aniket ^a  

^a GOVERNMENT MEDICAL COLLEGE   (India)

Author keywords

Estimated average glucose; Glycosylated haemoglobin; Insulin and analogues

Indexed keywords

GLUCOSE DEHYDROGENASE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; PYRUVATE DEHYDROGENASE;

ADULT; ARTICLE; DIABETIC PATIENT; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HEMOSTASIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

EID: 84902012254     PISSN: 09723560     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Mohan V, Sandeep S, Deepa R et al. Epidemiology of type 2 diabetes: Indian Scenario. Ind J Med Res 2007; 125: 217-30.
2. American Diabetes Association: Standards of medical care in diabetes-2007 (Position Statement). Diabetes Care 2007; 31(1): S12-S54.
3. Nathan DM, Judith Kuenen, Rikke Borg et al. For The A1c Derived Average Glucose (Adag) Study Group: Translating the A1c assay into estimated average glucose values. Diabetes Care 2008; 31: 1473-8.
4. Halimi S, Raskin P, Liebl A et al. Efficacy of biphasic insulin aspart in patients with type 2 diabetes. Clin Ther 2005; 27: S57-74.
5. Rolla AR, Rakel RE. Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues. Clin Ther 2005; 27: 1113-25.
6. Garber AJ, Wahlen J, Wahl T et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006; 8: 58-66.
7. Home PD, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapidacting insulin analogue, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol 1999; 55: 199-203.
8. Nazia Raja-Khan, Sarah S Warehime, Robert A Gabbay. Review of biphasic insulin aspart in the treatment of type 1 and 2 diabetes Vascular Health and Risk Management 2007; 3(6): 919-37.
9. Decode Study Group, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003; 26: 688-96.
10. Bonora E, Calcaterra F, Lombardi S et al. Plasma glucose levels throughout the day and HbA1c interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care 2001; 24: 2023-9.
11. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997; 20: 1822-6.
12. Bastyr EJ, Stuart CA, Brodows RG et al. (IOEZ Study Group): Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. Diabetes Care 2000; 23: 1236-41.
13. Nathan DM, John B Buse, Mayer B Davidson et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. Diabetes Care 2009; 32:193-203.